BRIEF-Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary Endpoint

Reuters

Jan 09

Jan 9 (Reuters) - PDS Biotechnology Corp PDSB.O:

PDS BIOTECH ANNOUNCES FDA ALIGNMENT ON USE OF PROGRESSION FREE SURVIVAL $(PFS)$ AS PRIMARY ENDPOINT
PDS BIOTECHNOLOGY CORP - AMENDMENT CHANGES PFS TO PRIMARY ENDPOINT FOR ACCELERATED APPROVAL
PDS BIOTECHNOLOGY CORP - MEDIAN OVERALL SURVIVAL REMAINS PRIMARY ENDPOINT FOR FULL APPROVAL

Source text: ID:nGNX6rC23C

Further company coverage: PDSB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602379713"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602379713\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602379713?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602379713","market":"us","top_or_hot":-1,"title":"BRIEF-Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary Endpoint","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary Endpoint</title></head><body><p><span>Jan 9 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/PDSB\">PDS Biotechnology</a> Corp <span>PDSB.O</span>:</p><ul><li><p>PDS BIOTECH ANNOUNCES FDA ALIGNMENT ON USE OF PROGRESSION FREE SURVIVAL <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> AS PRIMARY ENDPOINT</p></li><li><p>PDS BIOTECHNOLOGY CORP - AMENDMENT CHANGES PFS TO PRIMARY ENDPOINT FOR ACCELERATED APPROVAL</p></li><li><p>PDS BIOTECHNOLOGY CORP - MEDIAN OVERALL SURVIVAL REMAINS PRIMARY ENDPOINT FOR FULL APPROVAL</p></li></ul><p>Source text: <span>ID:nGNX6rC23C</span></p><p>Further company coverage: <span>PDSB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 21:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary Endpoint</title></head><body><p><span>Jan 9 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/PDSB\">PDS Biotechnology</a> Corp <span>PDSB.O</span>:</p><ul><li><p>PDS BIOTECH ANNOUNCES FDA ALIGNMENT ON USE OF PROGRESSION FREE SURVIVAL <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> AS PRIMARY ENDPOINT</p></li><li><p>PDS BIOTECHNOLOGY CORP - AMENDMENT CHANGES PFS TO PRIMARY ENDPOINT FOR ACCELERATED APPROVAL</p></li><li><p>PDS BIOTECHNOLOGY CORP - MEDIAN OVERALL SURVIVAL REMAINS PRIMARY ENDPOINT FOR FULL APPROVAL</p></li></ul><p>Source text: <span>ID:nGNX6rC23C</span></p><p>Further company coverage: <span>PDSB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PDSB","symbol_name":"PDS Biotechnology Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUABVC08Y:1","article_id":"2602379713","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602379713","pubTimestamp":1767967090,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary EndpointJan 9 (Reuters) - PDS Biotechnology Corp PDSB.O:PDS BIOTECH ANNOUNCES FDA ALIGNMENT ON USE OF PRO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PDSB":"PDS Biotechnology Corporation","BK4139":"生物科技"},"translate_title":"简介-Pds Biotech宣布与FDA就使用无进展生存期(Pfs)作为主要终点进行协调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PDSB":0.9},"content_text":"BRIEF-Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary EndpointJan 9 (Reuters) - PDS Biotechnology Corp PDSB.O:PDS BIOTECH ANNOUNCES FDA ALIGNMENT ON USE OF PROGRESSION FREE SURVIVAL $(PFS)$ AS PRIMARY ENDPOINTPDS BIOTECHNOLOGY CORP - AMENDMENT CHANGES PFS TO PRIMARY ENDPOINT FOR ACCELERATED APPROVALPDS BIOTECHNOLOGY CORP - MEDIAN OVERALL SURVIVAL REMAINS PRIMARY ENDPOINT FOR FULL APPROVALSource text: ID:nGNX6rC23CFurther company coverage: PDSB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}